Depot medroxyprogesterone acetate contraceptive injections and skeletal health

Women's Health

Volumn 6, Issue 3, 2010, Pages 339-342

  Renner, Regina Maria ^a   Edelman, Alison B ^b   Kaunitz, Andrew M ^c  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MEDROXYPROGESTERONE ACETATE; ORAL CONTRACEPTIVE AGENT;

BIRTH CONTROL; BONE DENSITY; DRUG EFFECT; DRUG SAFETY; DRUG USE; DRUG WITHDRAWAL; EDITORIAL; FRAGILITY FRACTURE; HORMONAL CONTRACEPTION; HUMAN; OSSIFICATION; OSTEOLYSIS; OSTEOPOROSIS; PATIENT COMPLIANCE; RISK BENEFIT ANALYSIS; SIDE EFFECT;

BONE DENSITY; CONTRACEPTION; CONTRACEPTIVE AGENTS, FEMALE; DELAYED-ACTION PREPARATIONS; FEMALE; HUMANS; MEDROXYPROGESTERONE ACETATE;

EID: 77952123671     PISSN: 17455057     EISSN: 17455065     Source Type: Journal    
DOI: 10.2217/whe.10.17     Document Type: Editorial

References (25)

1. Paschall S, Kaunitz AM: Depo-Provera and skeletal health: a survey of florida obstetrics and gynecologist physicians. Contraception 78 (5), 370-376 (2008).
2. Glasier A, Yan Y, Wellings K: How do health care professionals respond to advice on adverse side effects of contraceptive methods? The case of Depo Provera. Contraception 76 (1), 18-22 (2007).
3. McClung MR: The relationship between bone mineral density and fracture risk. Curr. Osteoporos. Rep. 3 (2), 57-63 (2005).
4. American College of Obstetrics and Gynecology: ACOG committee opinion no. 415: depot medroxyprogesterone acetate and bone effects. Obstet. Gynecol. 112 (3), 727-730 (2008). •• American College of Obstetrics and Gynecology recommendations on the use of Depo-Provera® (DMPA).
5. Berenson AB, Breitkopf CR, Grady JJ, Rickert VI, Thomas A: Effects of hormonal contraception on bone mineral density after 24 months of use. Obstet. Gynecol. 103 (5 Part 1), 899-906 (2004).
6. Kaunitz AM, Miller PD, Rice VM, Ross D, Mcclung MR: Bone mineral density in women aged 25-35 years receiving depot medroxyprogesterone acetate: recovery following discontinuation. Contraception 74 (2), 90-99 (2006). • Large prospective cohort of postmenopausal and premenopausal women and their BMD recovery after DMPA use versus nonhormonal contraception.
7. Cromer BA, Bonny AE, Stager M et al.: Bone mineral density in adolescent females using injectable or oral contraceptives: a 24-month prospective study. Fertil. Steril. 90 (6), 2060-2067 (2008).
8. Kaunitz AM, Arias R, Mcclung M: Bone density recovery after depot medroxyprogesterone acetate injectable contraception use. Contraception 77 (2), 67-76 (2008). •• Systematic review often clinical or observational studies between 1996 and 2006 investigating BMD recovery after DMPA use.
9. Guilbert ER, Brown JP, Kaunitz AM et al.: The use of depot- medroxyprogesterone acetate in contraception and its potential impact on skeletal health. Contraception 79 (3), 167-177 (2009).
10. Kaunitz AM, Darney PD, Ross D, Wolter KD, Speroff L: Subcutaneous DMPA vs. intramuscular DMPA: a 2-year randomized study of contraceptive efficacy and bone mineral density. Contraception 80 (1), 7-17 (2009).
11. Rosenberg L, Zhang Y, Constant D et al.: Bone status after cessation of use of injectable progestin contraceptives. Contraception 76 (6), 425-431 (2007).
12. Scholes D, Lacroix AZ, Ichikawa LE, Barlow WE, Ott SM: Change in bone mineral density among adolescent women using and discontinuing depot medroxyprogesterone acetate contraception. Arch. Pediatr. Adolesc. Med. 159 (2), 139-144 (2005).
13. Lopez LM, Grimes DA, Schulz KF, Curtis KM: Steroidal contraceptives: effect on bone fractures in women. Cochrane Database Syst. Rev. (4), CD006033 (2006).
14. Lappe JM, Stegman MR, Recker RR: The impact of lifestyle factors on stress fractures in female army recruits. Osteoporos. Int. 12 (1), 35-42 (2001).
15. Vestergaard P, Rejnmark L, Mosekilde L: The effects o depot medroxyprogesterone acetate and intrauterine device use on fracture risk in danish women. Contraception 78 (6), 459-464 (2008).
16. Watson KC, Lentz MJ, Cain KC: Associations between fracture incidence and use of depot medroxyprogesterone acetate and anti-epileptic drugs in women with developmental disabilities. Womens Health Issues 16 (6), 346-352 (2006).
17. Tolaymat LL, Kaunitz AM: Long-acting contraceptives in adolescents. Curr. Opin. Obstet. Gynecol. 19 (5), 453-460 (2007). •• Review of the current literature regarding the effects of hormonal oral and injectable contraceptives on adolescents' bone health.
18. WHO: Cardiovascular disease and use of oral and injectable progestogen-only contraceptives and combined injectable contraceptives. Results of an international, multicenter, case-control study. World Health Organization collaborative study of cardiovascular disease and steroid hormone contraception. Contraception 57 (5), 315-324 (1998).
19. Hubacher D, Lopez L, Steiner MJ, Dorflinger L: Menstrual pattern changes from levonorgestrel subdermal implants and DMPA: systematic review and evidence-based comparisons. Contraception 80 (2), 113-118 (2009).
20. Westhoff C: Depot-medroxyprogesterone acetate injection (Depo-Provera) : a highly effective contraceptive option with proven long-term safety. Contraception 68 (2), 75-87 (2003).
21. Kaunitz AM: Beyond the pill: new data and options in hormonal and intrauterine contraception. Am. J. Obstet. Gynecol. 192 (4), 998-1004 (2005).
22. Cromer BA, Scholes D, Berenson A, Cundy T, Clark MK, Kaunitz AM: Depot medroxyprogesterone acetate and bone mineral density in adolescents - the Black Box Warning: a position paper of the Society for Adolescent Medicine. J. Adolesc. Health. 39 (2), 296-301 (2006).
23. WHO: WHO statement on hormonal contraception and bone health. Wkly Epidemiol. Rec. 80 (35), 302-304 (2005). •• Brief review of the literature and their conclusions. Emphasizes that the benefts of DMPA should be weighed against the risks.
24. Black A: Canadian contraception consensus - update on depot medroxyprogesterone acetate (DMPA). J. Obstet. Gynaecol. Can. 28 (4), 305-313 (2006).
25. Guilbert ER, Kaunitz AM: Depo-Provera and skeletal health: reviewing the evidence; developing and disseminating a consensus. Contraception 79 (3), 165-166 (2009).